Antibodies to placental immunoregulatory ferritin with transfer of polyclonal lymphocytes arrest MCF-7 human breast cancer growth in a nude mouse model

Neoplasia

Volumn 9, Issue 6, 2007, Pages 487-494

  Halpern, Marisa ^a   Zahalka, Muayad A ^b   Traub, Leonid ^b   Moroz, Chaya ^b,c  

^a HASHARON HOSPITAL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

Antibody; Breast cancer; Gene; Immunomodulator; Immunotherapy

Indexed keywords

CASPASE 3; CYTOKINE; FERRITIN; FERRITIN ANTIBODY; GAMMA INTERFERON; PLACENTAL IMMUNOREGULATORY FERRITIN; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; FETUS GROWTH; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; NUDE MOUSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLACENTA; PLACENTA DEVELOPMENT; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 34250874475     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07259     Document Type: Article

References (29)

1. Emens LA, Reilly RT, and Jaffee EM (2005). Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 12, 1-17.
2. Rouas-Freiss N, Paul P, Dausset J, and Carosella ED (2000). HLA-G promotes immune tolerance. J Biol Regul Homeost Agents 14, 93-98.
3. Cavin LG, Venkatraman M, Factor VM, Kaur S, Schroeder I, Mercurio F, Beg AA, Thorgeirsson SS, and Arsura M (2004). Regulation of alpha-fetoprotein by nuclear factor-kappaB protects hepatocytes from tumor necrosis factor-alpha cytotoxicity during fetal liver development and hepatic oncogenesis. Cancer Res 64, 7030-7038.
4. Moroz C, Traub L, Maymon R, and Zahalka MA (2002). PLIF, a novel human ferritin subunit from placenta with immunosuppressive activity. J Biol Chem 277, 12901-12905.
5. Moroz C, Kupfer B, Twig S, and Parhami-Seren B (1985). Preparation and characterization of monoclonal antibodies specific to placenta ferritin. Clin Chim Acta 148, 111-118.
6. Parhami-Seren B and Moroz C (1986). A unique subunit structure of human placenta ferritin identified by the use of monoclonal antibodies. Ital J Clin Pathol 1, 17-23.
7. Zahalka MA, Barak V, Traub L, and Moroz C (2003). PLIF induces IL-10 production in monocytes; a calmodulin-p38 mitogen-activated protein kinase dependent pathway. FASEB J 17, 955-957.
8. Moroz Ch, Grunspan A, Zahalka MA, Traub L, Kodman Y, and Yaniv I (2006). Treatment of human bone marrow with recombinant placenta immunoregulator ferritin results in myelopoiesis and T-cell suppression through modulation of the cytokine-chemokine networks. Exp Hematol 34, 159-166.
9. Weinberger A, Halpern M, Zahalka MA, Quintana F, Traub L, and Moroz C (2003). Placental immunomodulator ferritin, a novel immunoregulator, suppresses experimental arthritis. Arthritis Rheum 48, 846-853.
10. Maymon R, Jauniaux E, Greenwold N, and Moroz Ch (2000). Localization of p43 placental isoferritin in human feto-maternal tissue interface. Am J Obstet Gynecol 182, 670-674.
11. Jauniaux E, Maymon R, Greenwold N, Hustin J, and Moroz Ch (2000). Diminished expression of placental isoferritin p43 component in first trimester abnormal pregnancies. Placenta 21, 408-411.
12. Nahum R, Brenner O, Zahalka MA, Traub L, Quintana F, and Moroz C (2004). Blocking of the placental immune-modulatory ferritin activates Th1 type cytokines and affects placenta development, fetal growth and the pregnancy outcome. Hum Reprod 19, 715-722.
13. Moroz Ch, Bessler H, Lurie Y, and Shaklai M (1987). A new monoclonal antibody enzymoassay for the specific measurement of placental ferritin isotype in hematologic malignancies. Exp Hematol 15, 258-262.
14. Rosen HR, Moroz Ch, Reiner A, Stierer M, Svec J, Reinerova M, Schemper M, and Jakesz R (1992). Expression of p43 in breast cancer tissue, correlation with prognostic parameters. Cancer Lett 67, 35-45.
15. Moroz Ch, Kan M, Chaimoff C, Marcus H, Kupfer B, and Cuckle S (1984). Ferritin-bearing lymphocytes in the diagnosis of breast cancer. Cancer 54, 84-89.
16. Gal R, Rath-Wolfson L, Rosenblatt Y, Halpern M, Schwartz A, and Koren R (2005). An improved technique for mitosis counting. Int J Surg Pathol 13, 161-165.
17. Odunsi K and Old LJ (2007). Tumor infiltrating lymphocytes: indicators of tumor-related immune responses. Cancer Immun 7, 3.
18. Tamura Y, Peng P, Liu K, Daou M, and Srivastava PK (1997). Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278, 117-120.
19. Kurzrock R (2001). Cytokine deregulation in cancer. Biomed Pharmacother 55, 543-547.
20. Vicari AP and Trinchieri G (2004). Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol Rev 202, 223-236.
21. Rosen HR, Moroz Ch, Reiner A, Reinerova M, Stierer M, Svec J, Schemper M, and Jakesz R (1992). Placental isoferritin associated p43 antigen correlates with features of high differential in breast cancer. Breast Cancer Res Treat 24, 17-26.
22. Shterman N, Kupfer B, and Moroz Ch (1991). Comparison of transferring receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiology 59, 19-25.
23. Rosen HR, Flex D, Stierer C, and Moroz Ch (1991). Monoclonal antibody CM-H-9 detects circulating placental isoferritin measured in the serum of patients with metastases of breast cancer. Cancer Lett 59, 145-151.
24. Rosen HR, Ausch C, Reiner G, Reinerova M, Svec J, Tuchler H, Schiessel R, and Moroz C (1994). Downregulation of lymphocyte mitogenesis by breast cancer-associated p43. Cancer Lett 82, 105-111.
25. Rosen HR, Ausch Ch, Reinerova M, Zaspin E, Renner K, Rosen AC, Schiessel R, and Moroz C (1998). Activated lymphocytes from breast cancer patients express the characteristics of type 2 helper cells - a possible role for breast cancer associated p43. Cancer Lett 127, 129-134.
26. Naujokat C, Sezer O, and Possinger K (1999). Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF-7 adenocarcinoma cells. Biochem Biophys Res Commun 264, 813-819.
27. Ruiz-Ruiz C, Ruiz de Almodovar C, Rodriguez A, Ortiz-Ferron G, Redondo JM, and Lopez-Rivas A (2004). The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J Biol Chem 279, 19712-19720.
28. Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, Wang A, and Clarke R (2005). Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 26, 1527-1535.
29. Gong MC, Latouche J-B, Krause A, Heston WDW, Bander NH, and Sadelain M (1999). Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1, 123-127.